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Abstract
Objective: e present study aims to investigate the eects of ouabain intracerebroventricular injection on BDNF levels in the amygdala and hippocampus of 
Wistar rats. Methods: Animals received a single intracerebroventricular injection of ouabain (10-3 and 10-2 M) or arti!cial cerebrospinal "uid and immediately, 
1h, 24h, or seven days a#er injection, BDNF levels were measured in the rat’s amygdala and hippocampus by sandwich-ELISA (n = 8 animals per group). Re-
sults: When evaluated immediately, 3h, or 24h a#er injection, ouabain in doses of 10-2 and 10-3 M does not alter BDNF levels in the amygdala and hippocampus. 
However, when evaluated seven days a#er injection, ouabain in 10-2 and 10-3 M, showed a signi!cant reduction in BDNF levels in both brain regions evaluated. 
Discussion: In conclusion, we propose that the ouabain decreased BDNF levels in the hippocampus and amygdala when assessed seven days a#er administra-
tion, supporting the Na/K ATPase hypothesis for bipolar illness.
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Resumo
Objetivo: O presente estudo tem como objetivo investigar os efeitos da injeção intracerebroventricular de ouabaína sobre os níveis de BDNF na amígdala e no 
hipocampo de ratos Wistar. Métodos: Os animais receberam uma única injeção intracerebroventricular de ouabaína (10-3 and 10-2 M) ou "uido cerebroespinhal 
arti!cial e, imediatamente, 3h, 24h ou sete dias após a injeção, os níveis de BDNF foram mensurados na amígdala e hipocampo dos ratos por ELISA sandwich (n 
= 8 animais por grupo). Resultados: Quando avaliados imediatamente após a injeção, 3h ou 24h, ouabaína nas doses 10-2 e 10-3 M não alterou os níveis de BDNF 
em ambas as estruturas avaliadas. Entretanto, quando avaliados sete dias após a injeção, ouabaína nas doses 10-2 e 10-3 M mostrou uma signi!cante redução nos 
níveis de BDNF em amígdala e hipocampo. Conclusão: Em conclusão, propõe-se que a administração de ouabaína diminuiu os níveis de BDNF em amígdala 
e hipocampo quando avaliados sete dias após a injeção, suportando a hipótese da participação da Na/K ATPase no transtorno bipolar.
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Introduction
Bipolar disorder (BD) is a prevalent, highly disabling, and chronic 
mood disorder, characterized by the presence of manic and depressive 
symptoms, but, the key clinical factor of the bipolar condition is a 
manic episode, characterized by an extremely elevated mood, energy, 
psychomotor activation, and sometimes psychosis. is is a disease 
with unclear pathophysiology and pathogenesis.
Sodium and potassium-activated adenosine triphosphatase 
(Na/K ATPase) plays an important role in regulating neural activity 
and neurotransmitter release1-7. Several studies have found direct and 
indirect evidence for a mood-state related decrease in the activity 
of the Na/K ATPase or Na pump in bipolar illness8. is change can 
directly alter neuronal activity9 and may be associated with activation 
of a second message in the absence of a !rst message (neurotrans-
mitter)10. e small reduction in sodium pump activity may alter the 
excitability of neurons and produces symptoms like-mania behavior, 
such as hyperactivity, aggressiveness, and risk-taking behavior9,11,12.
In more recent studies, BD has been associated with impairments 
in neuroplasticity and cell survival. Brain-derived neurotrophic fac-
tor (BDNF) is a member of the nerve growth factor family and has 
involvement in promoting synaptic e6cacy, neuronal connectivity 
and neuroplasticity13, being highly expressed in brain areas that are 
known to regulate cognitive and emotional behavior, such as the hi-
ppocampus and amygdala14. BDNF regulates neuronal development 
and survival, and controls the activity of many neurotransmitters, 
including the serotoninergic, dopaminergic, and glutamatergic 
systems15. Studies support the notion that changes in BDNF levels 
may be involved in the pathophysiology of BD16,17. Several studies 
show that serum BDNF is decreased during manic and depressive 
episodes16-21.
It is known that the intracerebroventricular (ICV) injection of 
ouabain (OUA), a potent Na/K ATPase pump inhibitor, induces 
hyperlocomotion22,23, which may persist for several days a#er a single 
injection24. us, the present study aims to investigate the eects 
of ICV administration of OUA in rats on BDNF expression in the 
hippocampus and amygdala immediately, 1h, or 24h, to mimic an 
acute episode of mania, and seven days, to mimic the persistence of 
a manic episode, a#er ouabain injection.
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Methods
Animals
We conducted the study using 96 (n = 8 animals per group) adult male 
Wistar rats (250-300 g – approximately 2 months of age) obtained 
from our breeding colony. e animals were housed 5 to a cage, on 
a 12-hour light/dark cycle (lights on at 7:00 am), with free access to 
food and water. All experimental procedures were carried out in ac-
cordance with the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals and the Brazilian Society for Neuroscience 
and Behaviour (SBNeC). is study was approved by the local ethics 
committee (Comitê de Ética em Uso de Animais da Universidade do 
Extremo Sul Catarinense, Protocol n° 536/2007), and all e"orts were 
made to minimize animal su"ering, to reduce the number of animals 
used, and to utilize alternatives to in vivo techniques.
Surgical procedure and treatment
Animals were intraperitoneally anesthetized with ketamine (80 mg/
kg) and xylasine (10 mg/kg). In a stereotaxic apparatus, the skin of 
the rat skull was removed and a 27 gauge 9 mm guide cannula was 
placed at 0.9 mm posterior to bregma, 1.5 mm right from de midline 
and 1.0 mm above the lateral brain ventricle. rough a 2 mm hole 
made at the cranial bone, a cannula was implanted 2.6 mm ventral 
to the superior surface of the skull, and #xed with jeweler acrylic ce-
ment. Animals were tested on the third day following surgery. A 30 
gauge cannula was #tted into the guide cannula and connected by a 
polyethylene tube to a microsyringe. e tip of the infusion cannula 
protruded 1.0 mm beyond the guide cannula aiming the right lateral 
brain ventricle. Each animal was administered 5 μl of either arti#cial 
cerebrospinal %uid (aCSF) or OUA (10-3 and 10-2 M; Sigma Chemical, 
Saint Louis, USA; dissolved in aCSF), over 30 sec23,25. 
Locomotor activity
Locomotor activity was measured immediately a&er (10 minutes 
approximately), 3h, 24h or seven days a&er ouabain or aCSF injec-
tion. Locomotor activity was assessed using the open-#eld task as 
previously described26. is task was performed in a 40 × 60 cm open 
#eld surrounded by 50 cm high walls, made of brown plywood, with 
the %oor divided into 12 equal rectangles by black lines. e animals 
were gently placed on the le& rear rectangle, and le& free to explore 
the arena for 5 min. Crossings of the black lines (locomotor activity/
horizontal activity) was counted.
BDNF levels measurement
BDNF levels in hippocampus and amygdala were measured imme-
diately a&er (10 minutes approximately), 3h, 24h or seven days a&er 
ouabain or aCSF injection by anti-BDNF sandwich-ELISA, according 
to the manufacturer instructions (Chemicon, USA). Brie%y, brain 
slices were homogenized in phosphate bu"er solution (PBS) with 1 
mM phenylmethylsulfonyl %uoride (PMSF) and 1 mM ethylene glycol 
tetraacetic acid (EGTA). Microtiter plates (96-well %at-bottom) were 
coated for 24 hr with the samples diluted 1:2 in sample diluent and 
standard curve ranged from 7.8 to 500 pg/ml of BNDF. e plates were 
then washed four times with sample diluent and a monoclonal anti-
-BNDF rabbit antibody diluted 1:1000 in sample diluent was added to 
each well and incubated for 3 hr at room temperature. A&er washing, 
a peroxidase conjugated anti-rabbit antibody (diluted 1:1000) was 
added to each well and incubated at room temp room temperature for 
1 h. A&er addition of streptavidin-enzyme, substrate and stop solution, 
the amount of BDNF was determined by absorbance in 450 nm. e 
standard curve demonstrates a direct relationship between Optical 
Density (OD) and BDNF concentration. Total protein was measured 
by Lowry’s method using bovine serum albumin as a standard.
Statistical analysis
Data are presented as mean and standard error of the mean. Di"e-
rences among the experimental groups were determined by one-way 
analysis of variance (ANOVA) followed by the Tukey post-hoc test. In 
all comparisons, statistical signi#cance was set at P < 0.05.
Results
Results for locomotor activity are shown in #gure 1. When evaluated 
immediately, 3h, 24h or seven days a&er ICV injection, the ouabain 
(10-2 and 10-3 M) administration increased rat spontaneous locomo-
tion, compared to the control group.
As illustrated in #gure 2, when evaluated immediately, 1h, 3h, or 
24h a&er ICV injection, ouabain in doses of 10-2 and 10-3 M does not 
alter BDNF levels in both the amygdala and hippocampus. However, 
when evaluated seven days a&er ICV injection (Figure 2D), ouabain 
in doses of 10-2 and 10-3 M, showed a signi#cant reduction in the 
BDNF levels in the amygdala and hippocampus.
Discussion
e Na/K ATPase (Na pump) maintains the concentration gradients 
of Na and K ions across the surface membrane of animal cells. It has 
been proposed that the ICV administration of ouabain in rats induces 
the neuronal ATPase hypoactivity, which is proposed to occur in ma-
nia and depression in humans. Previous studies showed that the ICV 
injection of ouabain induces hyperlocomotion (manic-like behavior), 
which persist for seven days a&er a single injection25,27, suggesting 
that inhibition of brain Na/K ATPase activity causes hyperactivity. 
We also demonstrated that when evaluated immediately, 3h, 24h or 
seven days a&er ICV injection, the ouabain administration increased 
rat spontaneous locomotion.
In the present study, we demonstrate that ouabain does not alter 
BDNF levels in the hippocampus and amygdala when evaluated im-
mediately a&er a single ICV injection. Inhibition of Na/K ATPase in-
duces alterations in intracellular ion concentrations, which can induce 
secondary changes in the activity of intracellular signal pathways28. 
However, these changes can occur in a late time course, as observed 
in the evaluation seven days following the injection. Moreover, BDNF 
protein levels may not be altered immediately a&er an ICV ouabain 
injection because synthesis or degradation of BDNF takes time. In this 
evaluation, we showed that ouabain causes a substantial reduction in 
BDNF levels of both structures in 10-2 and 10-3 M doses, when assessed 
seven days a&er administration. Previous studies from our research 
laboratory showed that a&er seven days the ouabain administration 
causes damage to lipids and proteins in the rat brain, but not imme-
diately a&er ouabain administration25,29. Whereas acute reactions to 
ouabain in animals have considerable homology to a manic episode 
(as reduction in the Na/K ATPase and consequent hyperactivity), the 
persistent e"ect of ouabain resembles aspects of illness progression. 
From these observations we suggest that ICV administration of 
ouabain is a good model to study the chronicity of BD. 
Palomino et al., in a study with bipolar patients that experienced 
a #rst psychotic episode, observed a dramatic decrease in levels of 
plasma BDNF of the patients30. Interestingly, BDNF levels in all ins-
tances progressively increased towards control values during 1-year 
follow-up subsequent to the #rst episode31, which should be related 
to the neuroprotective e"ect of the treatment used in this disease.
A growing body of evidence has showed that the pathophysiology 
of BD could be the result of deregulation of synaptic plasticity with 
downstream alterations of neurotrophins31. Neuroimaging studies 
suggest that decreased BDNF levels may account for structural brain 
changes in bipolar patients32,33. Kapczinski et al.17 recently showed that 
serum levels of BDNF are decreased during both manic and depressive 
mood episodes, being normalized in euthymia. Moreover, acute 
treatments with psichostimulant drugs, such as amphetamine, decrease 
BDNF levels in rat cerebral tissues accompanied with hyperlocomotion26.
is study presents the following limitations: a) this animal 
model mimics only aspects of manic episodes and b) only evaluated 
BDNF levels in the brain of rats, however it is known that other 
neurotrophins (NT-3, NT-4 and NGF)34-36 and other biochemical 
changes (oxidative protein, lipid and DNA damage)37,38 are involved 
in aspects of BD progression. 
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Figure 2. BDNF levels in rat hippocampus and amygdala immediately (A), 3h (B), 24h (C) or seven days (D) after ouabain or aCSF ICV injection. Bars 
represent means ± standard error of means of 7 animals. * P < 0.05 vs. aCSF group, according to ANOVA followed by the Tukey test.
Figure 1. Locomotor activity immediately (A), 3h (B), 24h (C) or seven days (D) after ouabain or aCSF ICV injection. Bars represent means ± standard error 
of means of 7 animals. * P < 0.05 vs. aCSF group, according to ANOVA followed by the Tukey test.
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Conclusion
Impairment of brain Na/K ATPase has an important role in the pa-
thogenesis of BD and these ndings suggest the possible link between 
BDNF and Na/K ATPase induced by ouabain in rats. Our ndings 
support the Na/K ATPase hypothesis for bipolar illness, but, further 
studies must be conducted to dene the model, explore its utility in 
understanding bipolar illness and in potential drug screening.
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